The opioid epidemic is and has been a national crisis, but it has hit West Virginia especially hard. In 2020 alone, approximately 1,291 overdose deaths were reported in West Virginia, nearly three times the national average. In West Virginia, opioids accounted for nearly 1,800 deaths in 2019 and 2020 combined.
While legal actions have since held some pharmaceutical manufacturers and distributors accountable, much of the damage had already been done. Now, the rise of illegal fentanyl continues to fuel addiction and overdose deaths, signaling continued struggle for communities ravaged by the ongoing crisis.
Gaps in coordination and oversight contributed to worsening the epidemic. For a long time, the FDA’s rules for safely prescribing and dispensing opioids were complex and evolving, even for medical professionals, often putting physicians and pharmacists in a bind.
While pharmacies sought clear guidance on safely prescribing and filling opioids to ensure compliance, differing state and federal regulations, combined with inconsistent access to technology and information, made it challenging for pharmacists (particularly independents) to balance patient safety with legitimate care needs. The absence of clear guidelines left some providers worried about over-prescribing and subjecting themselves to litigation, and others worried about their patients.
That brings us to today – where the pharmaceutical industry uses lobbying and Direct-to-Consumer (DTC) advertising to drive agendas that increase their profits and limit healthcare access and choice for patients. In 2024 alone, drug companies spent a record $31 million to lobby Washington DC on drug-pricing issues. As for patients, one study found that the amount of money spent on direct-to-consumer prescription drug advertising increased by 460% between 1997 and 2016.
The trend has shown no signs of slowing down. In 2024, Big Pharma spent over $5.3 billion on local and national TV ads, and an estimated $19.45 billion on digital advertising.
We’ve seen this playbook before. During the opioid epidemic, pharmaceutical manufacturers like Purdue developed highly sophisticated marketing and sales tactics to influence physicians prescribing habits. These tactics included sales-based incentive systems and targeted outreach to frequent prescribers. The result, discussed previously, was a tragedy for thousands of West Virginians and their families. It is essential that public and private leaders work together to ensure responsible regulation and oversight moving forward.
Regulators are finally starting to take notice. The FDA recently sent a letter to pharmaceutical companies warning them to remove “any noncompliant advertising and bring all promotional communications into compliance”. According to the letter, 88% of advertisements for top-selling drugs fail to adhere to the FDA’s “fair-balance” guidelines, and only 33% of them mention the potential harms associated with the drug in question.
While federal action against harmful advertising is a step in the right direction, the lessons of the opioid epidemic remind us that clear, fair, and transparent regulations protect patients, providers, pharmacies, and the health of our communities.
